Medical Systems Biology Group, University of Lübeck, Ratzeburger Allee 160, 23538 Lübeck, Germany; Institute for Cardiogenetics, University of Lübeck, Ratzeburger Allee 160, 23538 Lübeck, Germany; University Cancer Center Schleswig-Holstein, University Hospital of Schleswig- Holstein, Campus Lübeck, 23538 Lübeck.
Department of Hematology and Oncology, University Hospital of Schleswig-Holstein, Campus Lübeck, Ratzeburger Allee 160, 23538 Lübeck, Germany; Department of Hematology and Oncology, Federal Armed Forces Hospital Ulm, Oberer Eselsberg 40, 89081 Ulm.
Haematologica. 2022 Aug 1;107(8):1850-1863. doi: 10.3324/haematol.2021.279631.
High-grade B-cell lymphoma accompanied with double/triple-hit MYC and BCL2 and/or BCL6 rearrangements (HGBLDH/ TH) poses a cytogenetically-defined provisional entity among aggressive B-cell lymphomas that is traditionally associated with unfavorable prognosis. In order to better understand the mutational and molecular landscape of HGBLDH/ TH we here performed whole-exome sequencing and deep panel next-generation sequencing of 47 clinically annotated cases. Oncogenic drivers, mutational signatures and perturbed pathways were compared with data from follicular lymphoma (FL), diffuse large B-cell lymphoma (DLBCL) and Burkitt lymphoma (BL). We find an accumulation of oncogenic mutations in NOTCH, IL6/JAK/STAT and NFκB signaling pathways and delineate the mutational relationship within the continuum between FL/DLBCL, HGBL-DH/TH and BL. Further, we provide evidence of a molecular divergence between BCL2 and BCL6 rearranged HGBL-DH. Beyond a significant congruency with the C3/EZB DLBCL cluster in BCL2 rearranged cases on an exome-wide level, we observe an enrichment of the SBS6 mutation signature in BCL6 rearranged cases. Differential gene set enrichment and subsequent network propagation analysis according to cytogenetically defined subgroups revealed an impairment of TP53 and MYC pathway signaling in BCL2 rearranged cases, whereas BCL6 rearranged cases lacked this enrichment, but instead showed impairment of E2F targets. Intriguingly, HGBL-TH displayed intermediate mutational features considering all three aspects. This study elucidates a recurrent pattern of mutational events driving FL into MYC-driven BCL2-rearranged HGBL, unveiling the mutational pathogenesis of this provisional entity. Through this refinement of the molecular taxonomy for aggressive, germinal center-derived B-cell lymphomas, this calls into question the current World Health Organization classification system, especially regarding the status of MYC/BCL6- rearranged HGBL.
高分级 B 细胞淋巴瘤伴有双/三打击 MYC 和 BCL2 及/或 BCL6 重排(HGBLDH/TH),在侵袭性 B 细胞淋巴瘤中,其为一种基于细胞遗传学的暂定实体,传统上与不良预后相关。为了更好地了解 HGBLDH/TH 的突变和分子特征,我们对 47 例临床注释病例进行了全外显子测序和深度 panel 下一代测序。比较了致癌驱动因素、突变特征和失调途径与滤泡性淋巴瘤(FL)、弥漫性大 B 细胞淋巴瘤(DLBCL)和伯基特淋巴瘤(BL)的数据。我们发现 NOTCH、IL6/JAK/STAT 和 NFκB 信号通路中存在致癌突变的积累,并描绘了 FL/DLBCL、HGBL-DH/TH 和 BL 之间连续体的突变关系。此外,我们提供了证据表明,BCL2 和 BCL6 重排的 HGBL-DH 之间存在分子上的差异。除了在全外显子水平上与 BCL2 重排病例的 C3/EZB DLBCL 簇具有显著一致性外,我们还观察到 BCL6 重排病例中 SBS6 突变特征的富集。根据细胞遗传学定义的亚组进行差异基因集富集和随后的网络传播分析显示,BCL2 重排病例中 TP53 和 MYC 通路信号受损,而 BCL6 重排病例则没有这种富集,而是缺乏 E2F 靶点。有趣的是,考虑到所有三个方面,HGBL-TH 显示出中间的突变特征。这项研究阐明了驱动 FL 向 MYC 驱动的 BCL2 重排的 HGBL 的突变事件的复发模式,揭示了这一暂定实体的突变发病机制。通过对侵袭性、生发中心衍生的 B 细胞淋巴瘤的分子分类学进行细化,这对当前的世界卫生组织分类系统提出了质疑,特别是关于 MYC/BCL6-重排的 HGBL 的地位。